BioLife Solutions Wins Washington State 2015 Silver Award for Achievement in Medical Technology from Seattle Business Magazine

BOTHELL, Wash., March 2, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues  ("BioLife" or the "Company"), today announced that Seattle Business Magazine has named the Company its 2015 Silver Awardee for Achievement in Medical Technology.

Seattle Business Magazine Associate Publisher Michael Romoser described the environment for the awards program by stating, "While change in the health care business is not new, the pace of it is accelerating. Honorees in the 2015 Leaders in Health Care Awards program are at the forefront of unprecedented industry change as innovative problem solvers and inspirational leaders.  Among this year's 19 honorees are people who lead some of the largest and most important health care organizations in the region — be they hospitals, physician groups, research institutions or community programs. Their leadership is fostering creative change to organizations that are being challenged to raise the bar on the quality of patient safety and service while bringing new efficiency to their operations."

Judges for the 2015 Leaders in Health Care Awards included:

Leo Greenawalt, former president, Washington State Hospital Association
Mary McWilliams, former executive director, Washington Health Alliance
Chris Rivera, president and CEO, Washington Biotechnology & Biomedical Association
Roger Stark, M.D., health care policy analyst, Washington Policy Center

Mike Rice, BioLife President & CEO, stated, "This award is great recognition for our entire team.  Every team member really understands the positive impact our biopreservation tools can have on the development and commercialization of life saving cell and tissue-based regenerative medicine products and therapies.  Our culture of teamwork, quality, and customer service is very special and I'm very honored to lead such a dedicated team."

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol^® and CryoStor^® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE BioLife Solutions, Inc.

Related Links

http://www.biolifesolutions.com